RBC Capital on Intercept Pharma (ICPT): Benign Label Update Removes Key Overhang, Should Set Stage for Ocaliva Growth
Tweet Send to a Friend
RBC Capital maintains Outperform on Intercept Pharmaceuticals (NASDAQ: ICPT).Analyst Brian Abrahams comments "FDA has just updated Ocaliva's label with what ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
